mTOR and rapamycin: a review that leaves the human question open
A 2026 GeroScience review by Dudley W. Lamming follows rapamycin into geroscience and says the human healthspan question is unresolved.
mTOR and nutrient sensing
mTOR and nutrient sensing
mTOR is a nutrient-sensing pathway studied with rapamycin in models and in disease trials. This site gives no dose and no recommendation. Human lifespan extension is not established here. A disease approval is not an anti-aging approval.
Latest discoveries
Featured research
Bench to bedside: is rapamycin headed for the docTOR?
Lamming DW
Lamming describes rapamycin as an mTOR inhibitor studied from transplant medicine into geroscience. The abstract says model-organism work has reported effects on lifespan and organ function, that human trials for diseases of aging exist, and that side effects may limit translation. It concludes that whether rapamycin, or a similar mTOR inhibitor, can extend human healthspan and lifespan is still unresolved.
This is one review, not a pooled human trial. This site does not extract a dose, a schedule, or a recommendation.
The future
The open questions are measurement, safety and whether a change in a marker changes how people function. Those are research questions, not results.
Evidence grades stay in the Longevity Explorer. A disease study is not an anti-aging approval. Explorer
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.